Articles On ICSGlobal (ASX:ICS)

Title Source Codes Date
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead ICS 1 year ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead ICS 1 year ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead ICS 1 year ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead ICS 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead ICS 1 year ago
CLOSING BELL: The ASX engine rooms roar to life, delivering a 1.2% touch worthy of Midas himself

What a solid day it’s been for the ASX today, with the benchmark maintaining a strong run past +1.1% for the afternoon, to finish at +1.18% when the bell finally rang, and the old ladies running the ASX called “pencils down” and everyone go...

Stockhead ICS 1 year ago
ICS Global (ASX:ICS) advises shareholders to knock back DWY takeover

ICS Global (ICS) asks shareholders to reject an off-market takeover bid by Dawney & Co’s subsidiary, DWY ICS says the offer of 20 cents each “materially undervalues” ICS shares and would see the company only receive $2.12 million...

themarketherald.com.au ICS 1 year ago
Market Highlights: Tesla, oil prices slump, and 5 ASX small caps to watch on Wednesday

The ASX will open higher this morning, defying a slump in New York Tesla shares plunged 12% Oil prices tumbled on recession fears   Aussie shares are set to open higher this morning despite a fall in New York. At 8am AEDT, the ASX 200 Jan...

Stockhead ICS 1 year ago
Sandon’s Kiwi investment Dawney lobs bid for ASX-listed ICSGlobal

NZX-listed investment company Dawney & Co is getting ready to lob a bid for ASX-listed peer ICSGlobal, which has been suspended from trading for more than 1½ years.

AFR ICS 2 years ago
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Stockhead ICS 2 years ago
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Stockhead ICS 2 years ago
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Stockhead ICS 2 years ago
Check Up: Money managers are still bullish on Healthcare; here’s what they said

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead ICS 2 years ago
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Stockhead ICS 2 years ago
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Stockhead ICS 2 years ago
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Stockhead ICS 2 years ago
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Stockhead ICS 2 years ago
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

Stockhead ICS 2 years ago
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Stockhead ICS 3 years ago
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Stockhead ICS 3 years ago
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead ICS 3 years ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead ICS 3 years ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead ICS 3 years ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead ICS 3 years ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead ICS 3 years ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead ICS 3 years ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead ICS 3 years ago
Closing Bell: Today’s biggest small cap movers on the ASX

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Stockhead ICS 3 years ago
Last Orders: ASX falls 0.1 per cent despite Airtasker debut

The ASX finished the day slightly down despite Airtasker’s (ASX:ART) positive debut. The Aussie tech icon finished the day up over 60 per cent. However, the broader ASX sector finished the day down with the ASX 200 falling 0.11 per cent to...

Stockhead ICS 3 years ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead ICS 3 years ago
The ICSGlobal (ASX:ICS) share price has climbed 13% today. Here’s why.

The ICSGlobal Ltd (ASX: ICS) share price has leapt up 13% today after the company provided a positive guidance update for FY21. At the time of writing, the ICSGlobal share is price is trading at $2.09. Strong performance in FY21 The medica...

Motley Fool ICS 4 years ago
Share Buybacks – Who’s Doing It? – 17-12-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Check-up: Lasers and fatty livers won in biotech this month

Here’s our monthly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, 92 saw their share prices fall, 32 improved and 13 were flat. >> Scroll down for a table showing the performance of small...

Stockhead ICS 5 years ago
Share Buybacks – Who’s Doing It? – 11-12-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 04-12-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 27-11-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 20-11-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 13-11-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 06-11-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 30-10-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 23-10-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Five Market Moving Healthcare Stocks – SDX, ICS, ALT, MEB, NEU

Australian health care sector is growing potentially by generating significant profits in a short period, and that is something the investors are also closely monitoring. Australia’s public healthcare system is one of the world’s best, join...

Kalkine Media ICS 5 years ago
Share Buybacks – Who’s Doing It? – 16-10-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
10 at 10: These ASX stocks are on the move this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead ICS 5 years ago
Share Buybacks – Who’s Doing It? – 09-10-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 02-10-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 25-09-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 18-09-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? – 11-09-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago
Share Buybacks – Who’s Doing It? 04-09-2019

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

FNArena ICS 5 years ago